Hensoldt's Half-Year Triumph Meets a Wall of Skepticism: The €10.4 Billion Backlog That Couldn't Lift the Shares

Hensoldt's record H1 order intake and backlog fail to lift shares as guidance stays unchanged, signaling growth limits and split analyst views.

The optics of Friday's session were jarring for anyone tracking Hensoldt. The defence-electronics group had just delivered a set of first-half numbers that most industrial companies would envy — order intake effectively doubling, a backlog sailing past the €10 billion mark, and margins grinding higher. The market's response? A 4.64 percent markdown that left the stock at €79.76 and among the MDAX's worst performers of the day.

The disconnect is not as puzzling as it first appears. For months, the shares have been trading on expectations as much as on fundamentals, and Friday's report card revealed a ceiling that investors had not fully priced in: management chose to reaffirm its annual guidance rather than raise it.

The Numbers Were, By Any Measure, Strong

The headline figures from the first six months of 2026 tell a story of robust momentum. Revenue climbed 23.6 percent to €1.167 billion, while adjusted EBITDA advanced 28.5 percent to €137 million, lifting the corresponding margin from 11.3 percent to 11.8 percent. The order book was the real showstopper: new business more than doubled to €2.812 billion, up from €1.405 billion in the prior-year period, pushing the total backlog to a record €10.356 billion.

The Optronics division provided the standout performance, with order intake leaping from €164 million to €971 million, driven largely by major contracts tied to the Puma and Schakal armoured fighting vehicles. The figures underscore how deeply the current demand cycle for land systems is running.

Even the group's cash flow, while still negative, showed meaningful improvement. The adjusted free cash flow came in at minus €136 million, a solid step up from the minus €181 million recorded a year earlier — a seasonal pattern that typically flips decisively in the second half as deliveries and customer acceptances concentrate in the fourth quarter.

Guidance Held Steady, and That Was the Problem

For all the operational strength, the market's attention fixed on what was not said. With the first half running ahead of expectations, many traders had positioned for an upward revision to the full-year outlook. Instead, the board stuck to its existing targets: revenue of roughly €2.75 billion for 2026, an adjusted EBITDA margin between 18.5 and 19.0 percent, and a book-to-bill ratio in the range of 1.5x to 2.0x.

The absence of a guidance hike, despite the record numbers, was widely read as a signal that the growth trajectory may be approaching its limits. That interpretation found support in the analyst commentary that followed, though the sell-side response was anything but uniform.

A Split Verdict From the Sell Side

The range of analyst opinions published on Friday is striking. At one end, mwb research reiterated its "Sell" recommendation with a price target of €62.00, pointing to a rich valuation of 13.4x EV/EBITDA based on 2028 estimates and questioning whether the current order intake can be sustained beyond that horizon. At the other, Jefferies maintained its "Buy" stance with a target of €94.00, praising the record backlog and the slight beat against its own projections.

Between those poles, Warburg Research confirmed its "Buy" rating with a €91.00 target, describing the second quarter as convincing given that revenue growth was delivered profitably. JPMorgan, meanwhile, held firm at "Neutral" with an €85.00 target, arguing that Hensoldt remains the most richly valued defence name in its coverage universe — and that peers such as Renk offer more compelling upside.

That last point touches on a broader dynamic weighing on the stock. Hensoldt has corrected less sharply than Rheinmetall or Renk in recent months, leaving its valuation with little room for error. Some investors have consequently rotated toward Rheinmetall, which has enjoyed a run of positive news and a fresh buy signal. The valuation question, rather than any deterioration in the underlying business, is what continues to cap the share price.

Distance From the Peak, and a Path Forward

Friday's decline widened the gap to the 52-week high of €115.10, reached back in October, to roughly 30.7 percent. Even so, the shares have gained 5.92 percent over the past 30 days and remain in positive territory for the year to date.

The company itself is not short of potential catalysts. Late July brought the opening of a new corporate campus, inaugurated alongside Defence Minister Boris Pistorius, with a focus on high-performance radars such as the TRML-4D. The market is also watching for the luWES tender for underwater weapon systems, expected in August. On the calendar ahead: a presentation at the Commerzbank & ODDO corporate conference in Frankfurt on September 2, the nine-month results on November 5, and a capital markets day in London on November 10.

Until then, the debate will rage over whether the current order momentum is sustainable or whether the valuation concerns voiced by mwb research carry more weight. What is clear is that Hensoldt's problem is not demand — it is the price of admission. With a record backlog of €10.4 billion providing exceptional visibility into future growth, the shares may ultimately reward patience. But for now, the market is asking how much of that growth is already in the price.